Dopamine D2 receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient

Biological Psychiatry

Volumn 50, Issue 11, 2001, Pages 873-883

  Kapur, Shitij ^a,b   Remington, Gary ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antipsychotics; Atypical; Dopamine; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; NEUROLEPTIC AGENT; PROLACTIN; SEROTONIN;

CLINICAL FEATURE; CLINICAL STUDY; COGNITION; CONFERENCE PAPER; DISSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOOD; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIBENZOTHIAZEPINES; HUMANS; MODELS, NEUROLOGICAL; PIRENZEPINE; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; SULPIRIDE;

EID: 0035660215     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01251-3     Document Type: Conference Paper

References (95)

1. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
2. Management decisions on priority pipeline products - MDL 100907
3. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
4. Differentiation of classical and novel antipsychotics using animal models
5. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro
6. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
7. Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist
8. D-2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects
9. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome
10. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: Results of a multicentre, double-blind study
11. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response
12. Amisulpride - A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
13. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
14. The efficacy of drug treatments for dysthymia: A systematic review and meta-analysis
15. Special feature: Childhood personality characteristics of schizophrenia: Manifestations of, or risk factors for, the disorder?
16. Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study
17. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial
18. "Schizotaxia": Clinical implications and new directions for research
19. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients
20. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects
21. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients
22. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs
23. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: Three efficacy studies
24. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
25. Time course of central nervous dopamine-D-2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia
26. Drug treatment of schizophrenia: Myths and realities
27. Neuroleptic withdrawal in schizophrenic patients. A review of the literature
28. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs
29. Receptor binding of N-(methyl-11C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET)
30. The history of clozapine
31. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
32. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia
33. Increased dopamine D(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine
34. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action
35. Does fast dissociation from the dopamine D2 receptors explain atypical antipsychotic action - A new hypothesis
36. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
37. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy
38. 5-HT2 and D-2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
39. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
40. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D-2 receptors: Implications for the therapeutics of schizophrenia
41. Increased dopamine transmission in schizophrenia: Relationship to illness phases
42. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
43. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia
44. Is amisulpride an 'atypical' atypical antipsychotic agent?
45. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
46. Overcoming the neuroleptic-induced deficit syndrome: Clinical observations with remoxipride
47. Remoxipride and raclopride - Pharmacological background and clinical outcome
48. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L(-beta-11C) DOPA and PET
49. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
50. In vivo characteristics of dopamine D-2 receptor occupancy by amisulpride in schizophrenia
51. Schizotaxia, schizotypy and schizophrenia
52. Schizotaxia revisited
53. The role of serotonin in antipsychotic drug action
54. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values
55. The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs
56. Major psychosis and dopamine: Controversial features and some suggestions
57. Hyperactivity of associations in psychosis
58. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients
59. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects - A double-blind PET study of schizophrenic patients
60. Positron emission tomography finding of a high striatal D-2 receptor occupancy in olanzapine-treated patients
61. A PET study of 5-HT2 and D-2 dopamine receptor occupancy induced by olanzapine in healthy subjects
62. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity
63. Glutamate receptor dysfunction and schizophrenia
64. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
65. Prolactin in schizophrenia
66. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
67. Children's self-reported psychotic symptoms and adult schizophreniform disorder: A 15-year longitudinal study
68. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs. haloperidol
69. Cognitive and behavioural functioning in men with schizophrenia both before and shortly after first admission to hospital. Cross-sectional analysis
70. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia
71. Safety profile of amisulpride in short- and long-term use
72. Elevated dopa decarboxylase activity in living brain of patients with psychosis
73. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia
74. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects
75. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
76. Brain receptors for antipsychotic drugs and dopamine: Direct binding assays
77. Dopamine D4 receptors elevated in schizophrenia
78. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons
79. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors
80. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
81. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine - A double-blind, placebo-controlled study
82. Quetiapine in patients with schizophrenia - A high- and low-dose double-blind comparison with placebo
83. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol
84. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors
85. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: Role of 5-HT2 receptor and alpha(1)-adrenoreceptor antagonism
86. Binding of antipsychotic drugs to cortical 5-HT2A receptors: A PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients
87. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia
88. Toward reformulating the diagnosis of schizophrenia
89. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
90. Clozapine versus typical neuroleptic medication for schizophrenia
91. Childhood precursors of schizophrenia: Facial expressions of emotion
92. Dopamine blockade and clinical response: Evidence for two biological subgroups of schizophrenia
93. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors
94. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia